Fosamax Osteonecrosis of the Jaw Causation: Does Fosamax cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Clinical Inquiry

The legacy of general health and science information has long served as a foundational resource for public understanding of medical conditions and therapeutic interventions. Within this broad domain, discussions of bone health and the management of osteoporosis have historically emphasized the benefits of bisphosphonate therapies, such as Fosamax, in reducing fracture risk. This educational heritage provided a balanced overview of treatment efficacy and potential side effects, framed within a context of patient safety and informed consent. As the scope of health communication evolves, a natural pivot occurs toward more specialized areas of clinical concern. One such area involves the transition from general therapeutic guidance to the specific examination of adverse outcomes linked to pharmaceutical exposure. In this shift, the focus narrows to the relationship between Fosamax use and the risk of osteonecrosis of the jaw—a condition that has emerged as a significant consideration in dental and medical practice. This transition moves the discussion from broad health literacy to a targeted occupational exposure concern. For healthcare professionals, particularly dentists and oral surgeons, understanding the potential causation between Fosamax and jaw necrosis is critical for risk assessment and patient management. The pivot thus reframes the legacy of general health information into a practical, evidence-informed inquiry relevant to clinical decision-making and professional vigilance.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the general understanding of bisphosphonate therapy, we now focus specifically on Fosamax (alendronate sodium) and its association with osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ is a condition characterized by exposed, necrotic bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Evidence Linking Fosamax to ONJ

Mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate that inhibits bone resorption by osteoclasts. This suppression of bone turnover can lead to impaired bone remodeling and microdamage accumulation, particularly in the jawbone, which has unique structural and functional characteristics. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's high turnover rate and susceptibility to local infections and trauma may contribute to the development of ONJ in patients on bisphosphonate therapy. Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping Fosamax, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse event, its incidence in clinical trials was not significantly different from placebo, indicating that other factors may contribute to its occurrence.

Warnings, Causation Considerations, and Clinical Implications

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on Osteonecrosis of the Jaw (section 5.4) that describes the condition, associated risk factors, and recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also notes that in placebo-controlled studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, which may influence the perceived strength of the causal association. Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax use and ONJ onset, the presence of other risk factors, and the exclusion of alternative causes. The label states that ONJ can occur spontaneously and is generally associated with dental procedures or infections, making it challenging to attribute causation solely to Fosamax. The recurrence of symptoms upon rechallenge with bisphosphonates supports a drug-related effect in some patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients who develop ONJ while on Fosamax, the label advises discontinuation if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax is associated with an increased risk of ONJ, particularly in patients with additional risk factors such as dental procedures, cancer, or concomitant medications. The mechanism involves bisphosphonate-induced suppression of bone turnover, and the timeline for symptom onset can range from days to months. Warnings in the prescribing information address this risk, but the low incidence in clinical trials and the multifactorial nature of ONJ complicate direct causation. Patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis treatment against the potential risk of ONJ, especially in those with identifiable risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the relationship between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with osteonecrosis of the jaw (ONJ), a condition involving exposed necrotic bone in the jaw. The risk is higher in patients with additional risk factors such as dental procedures, cancer, or concomitant medications. The mechanism involves suppression of bone turnover leading to impaired remodeling. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

How long after starting Fosamax can osteonecrosis of the jaw occur?

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months. Most patients experience relief after stopping the drug, but some may have recurrence upon rechallenge. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What are the risk factors for developing osteonecrosis of the jaw while on Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Duration of bisphosphonate use also increases risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.